References in periodicals archive ?
a subsidiary of BTG plc listed on the London Stock Exchange: BGC), a leading international technology transfer company, announced today it has available for license a novel peptide that has potential use in the treatment of acute inflammatory conditions and autoimmune diseases including surgical tissue reperfusion injury, systemic lupus, rheumatoid arthritis, Sjogren's disease, scleroderma, dermatomyositis, and multiple sclerosis.